🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Springer Nature AG & Co. KGaA (ETR:SPG)
Germany flag Germany · Delayed Price · Currency is EUR
22.45
-0.20 (-0.88%)
At close: Nov 20, 2026
← View all transcripts

Earnings Call: Q3 2026

Nov 17, 2026

Summary

Nine-month underlying revenue rose 6% and AOP 8%, with research driving growth and free cash flow reaching €244 million. FY 2026 guidance calls for at least 6% revenue growth and 30 bps of underlying margin improvement.

Operator

Ladies and gentlemen, welcome to the nine-month result 2026 conference call. I am Sandra, the Chorus Call operator. I would like to remind you that all participants have been listening only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it is my pleasure to hand over to Tom Waldron, Head of Investor Relations. Please go ahead, sir.

Tom Waldron
Head of Investor Relations, Springer Nature

Thank you, Sandra. Good afternoon, everyone. Welcome to the Springer Nature nine-month 2026 results call. I'm Tom Waldron, Head of Investor Relations, and I'm here in Barcelona with our CEO, Frank Vrancken Peeters, and CFO, Patric Somlo, to participate in the Morgan Stanley European TMT Conference here over the next couple of days. But before that, we'll move to our nine-month results, which we published this morning. Frank will cover the business and financial update, Patric will introduce himself, and we'll move to Q&A. Before handing over, let me briefly remind you, for revenues and adjusted operating profit, we present both reported figures based on actual currency rates and portfolio composition, and underlying growth rates, which exclude currency and portfolio effects to ensure a like-for-like comparison. Our financial guidance for 2026 is based on the expected underlying performance of the business, excluding FX and portfolio changes.

When growth rates are mentioned in this presentation, they are underlying unless otherwise specified. With that, I will now hand over to Frank.

Frank Vrancken Peeters
CEO, Springer Nature

Yeah. Thank you, Tom. A warm welcome from my side. Let's start with a brief overview of the highlights. Our results show continued good momentum. Revenue grew by 6% in underlying terms and AOP by 8%. Our research segment continues to be the main growth driver, with strong performance across our journal portfolios. Growth was again driven by our leadership in open access and our investments in technology and AI. We've delivered another strong cash flow performance with leverage well within our target range. Given this strong performance and the visibility we have into the remainder of the year, we are again updating our 2026 guidance. We now expect underlying revenue growth of at least 6%, with AOP margin improving by at least 30 basis points in underlying terms. As a reminder, Springer Nature operates in three attractive markets where we hold strong positions.

Research remains by far our largest segment. In the first nine months, it represented almost 80% of group revenue and 90% of adjusted operating profit. This reflects the scale and quality and resilience of our research portfolio. We are the second-largest publisher of academic journals by some distance. We have the largest share of the top 50 journals by impact factor, and we are the world's largest publisher of academic books. Before turning to a business update, as usual, here are a few recent examples of research from our journals. First, our Neanderthal relatives. A paper in Scientific Reports looks at how they lived 75,000 years ago. One individual had recovered from a severe facial injury, and that probably meant others in the group cared for them as they recovered. There is also evidence of intentional burial. Together, this all points to a complex social life for our ancient cousins.

Second, in the middle, the world's oldest shipwreck. It was found off the coast of Turkey, with a cargo of amphorae having sunk more than 4,000 years ago. This paper appeared in the Journal of Maritime Archaeology, a Springer title, and received lots of press attention, as you may have seen. Third, a look at the future. In July, Nature Chemistry published a paper on new techniques that use light to trigger chemical reactions inside living cells. In effect, the cells become controllable mini-factories that can make new chemicals. The authors hope that this could lay the foundations for applications in precision medicine. One of the authors was actually Karl Deisseroth. A few months later, in October, he won the 2026 Nobel Prize in Physiology or Medicine, together with Peter Hegemann and Georg Nagel. The prize recognized their earlier work on using light to control cell activity.

All of this year's laureates in medicine, physics, chemistry, and economics have published with Springer Nature, and a selection of their papers and book chapters have been gathered on our website. Over the last 50 years, more than three-quarters of Nobel laureates have published in Nature titles during their careers, and more than 90% have published somewhere across our portfolio. This is the role we play, making trusted knowledge accessible. Our 3,000 journals cover hundreds of fields, and every paper we publish can become a building block for future research. Now, on to our financial performance in the first nine months of 2026. Research delivered another strong performance. Revenue increased by 7% in underlying terms, while adjusted operating profit grew by 8%. The 2026 renewal season was completed successfully, and the 2027 season began in September with renewals progressing as expected.

Growth in our journal portfolios were broad-based across our full open access Nature and Springer portfolios. Our double-digit article publication growth continued to outpace the market, which we estimate grew at around 8% in the period. Submission growth has continued at similar levels seen earlier this year, with good growth seen across the portfolio and across all major regions. We continue to drive open access adoption. We signed 20 new transformative agreements, bringing the total to more than 100 and covering more than 4,500 institutions. So far in 2026, we have launched 54 new journals, including npj Nephrology, Scientific Reviews, BMC Sustainability, and Discover Cybersecurity. Our growth in journals is being supported by the AI strategy we outlined in our full-year presentation in March. SNAPP, our AI article processing platform, continues to onboard new journals. Year to date, over 62% of our submissions have been processed through SNAPP.

Our Journal Finder brings new authors to Springer Nature. Our AI tools are helping editors find the right reviewers faster, and our transfer recommender is ensuring that good papers rejected on scope are retained within our ecosystem. AI tools are also helping our teams to ensure research integrity across the portfolio. We recently established a research partnership with Google DeepMind on a project to design an AI-powered assistant for reviewers. That project is part of our commitment to creating a frictionless publication process. Together with the team at Google DeepMind, we will explore how technology can help create a more rewarding reviewer experience. Nature Research Assistant, our own AI tool for researchers, is well on track for launch in early 2027. ARC3 is seeing good traction. It provides a partnership model which gives researchers, clinicians, and R&D teams access to our trusted scientific content within AI-powered environments.

This represents the next step in the evolution of our long-standing text and data mining business. In books, revenues increased with growth in print and digital. Nature Books launched its first three titles at the Frankfurt Book Fair in October, combining the strength of the Nature brand with our leading position in this market. Research AOP grew faster than revenue, reflecting operating leverage and ongoing efficiency improvements. Finally, during Q3, we completed the disposal of our consumer media business, further increasing our focus in the core research segment. Let's now turn to developments in our other two segments, health and education. Turning first to health, we saw revenues and AOP increase by 1%. Performance benefited from the stabilization of advertising spending in regional markets, partially offset by weaker performance in the events business in DACH. International Healthcare grew modestly despite a challenging backdrop for pharma marketing spending.

The Netherlands faced a strong comparison with 2025, which benefited from a new edition of the Schlichting test. Turning to education, revenue and AOP increased by 4% and 5% respectively. Growth was led by Argentina, Southern Africa, and Poland, partially offset by more challenging conditions in Spain and Mexico. A large government-related order in Argentina was received in Q3, later than in the prior year. Before turning to the financials in a bit more detail, I'd like to step back and look at one of the fundamental drivers of growth for the research industry and for Springer Nature, the growing global reach of research ecosystems. Commercial academic publishing began in the 19th century. In its first 100 years, the industry was based on subscriptions and print journals for researchers, largely in Western Europe and the U.S. Over the last 30 years, the global research landscape has experienced extraordinary change.

Prior to the 1990s, more than 70% of research articles came from authors in the U.S. or Western Europe, and today, that is almost fully reversed, with over 60% now coming from the rest of the world. This reflects the continued growth in R&D investment around the world, and particularly in China. At the same time, the shift from print to digital platforms has made it easier for researchers everywhere to access knowledge, collaborate, and publish their work. We see this broadening of research not only in article volumes, but also in citation share. As new markets mature, the quality of research rises. China demonstrates the potential with a citation share that now leads the world and exceeds its share of articles.

When you look at these relative shares, it's important to remember that the traditional research centers in the U.S. and Western Europe have still grown their research articles and their citations substantially over the period. Their relative dominance prior to the 1990s has simply given way to a more global spread of academic and scientific progress. Springer Nature has been investing behind these trends for many years. We've built strong local infrastructure. We've invested in local publishing teams, we have built deep relations with institutions and research communities, and we have created a broad network of editors and reviewers around the world. We also continue to launch journals in growing fields and regions while helping researchers find the right publication route across our portfolio. The combination of the strength of our portfolio with investments in the regions driving growth has allowed us to grow faster than the market.

It also positions us well to continue to do so in the future. I'll now provide a short financial update. This slide presents five important performance indicators for our business. We delivered a strong nine-month performance across each of them, with strong revenue growth, underlying margin expansion, and cash generation. The next slide summarizes that performance in detail as usual. We delivered underlying growth in revenues and AOP across all three segments in the nine months, and our group AOP margin saw an underlying improvement of 36 basis points. Reported margin also includes a 30 basis point benefit from the disposal of the consumer media business. FX still had a negative impact on reported growth rates, but the headwind eased as the dollar and education currencies stabilized. Turning to cash and leverage. I'm pleased to report that our cash generation in the first nine months of 2026 was very strong.

Free cash flow rose by EUR 69 million to EUR 244 million, supported by improved operating performance and lower interest payments. Lower interest and fee payments reflected both lower average debt levels and interest rates and timing benefits, including from the issue of promissory notes in 2025. Strong nine-month cash generation supported continued delevering, and we enter the quarter at 1.6 net debt to EBITDA. Based upon the performance in the nine months and ongoing business momentum, we've again updated our full year 2026 guidance. We expect underlying growth in revenues of at least 6%, with underlying improvement in the AOP margin of also at least 30 basis points. Finally, to summarize, we're proud to have delivered a strong performance in the first nine months of 2026, demonstrating the strength of our business, both in terms of financial performance and strategic execution.

Research is the key driver of that momentum, powered by our leadership in open access, our geographic footprint, and our commitment to embracing AI across the portfolio. Having covered the year to September and our outlook, I want to touch on one important thing that has happened since quarter end. Patric has joined the team as CFO, and Patric is here with us today, so I'll hand over to him to introduce himself.

Patric Somlo
CFO, Springer Nature

Thank you, Frank. It is a pleasure to join the call today. I joined Springer Nature two weeks ago. My immediate priority is to get to know the business, our people, and key stakeholders. What attracted me to Springer Nature was the combination of a clear purpose, outstanding brands, and strong market positions. I am joining a business with a clear potential for sustainable growth in revenue, profit, and cash. My first impression has reinforced that view. I have found a business with a strong portfolio and strategy, talented and committed colleagues, and a clear focus on execution and investment for the long term. That is a strong base from which to deliver compounding growth. I look forward to working with colleagues to build on that with further optimizations, both operationally and in areas such as finance and tax.

I look forward to meeting many of you over the coming months. I will now hand back to Tom for Q&A.

Tom Waldron
Head of Investor Relations, Springer Nature

Thank you. We will now move to Q&A. As a reminder, we ask that each analyst limit themselves to two questions initially. If you do have additional questions, we will be happy to come back to you. With that, I will hand the call back to Sandra.

Operator

Thank you. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on the telephone. You will hear a tone to confirm that you have entered the queue. If you wish to remove yourself from the question queue, you may press star and two. Questioners on the phone are requested to disable the loudspeaker mode while asking a question. Anyone who has a question may press star and one at this time. Our first question comes from Nick Dempsey from Barclays. Please go ahead.

Nick Dempsey
Analyst, Barclays

Yeah. Good afternoon, guys. First of all, it's clear that submission and publication volume growth in full open access is very strong at the moment and continues to be so. Full open access is excluded from most of your transformative agreements, I believe, so you just get the benefit of that volume growth straight away into your revenues. Could the consortia for many countries now start to move to include full open access journals in their TAs, and therefore that would mean the benefits of that publication volume growth are spread out a bit more over time or smoothed, which could slow overall research growth? That's the first question.

Second one, as we watch your net debt to EBITDA head down towards 1.5 x at the bottom of your stated range, and you've shown over time that the group can bear quite a lot of leverage, what are your thoughts about large M&A deals within your space at this moment?

Frank Vrancken Peeters
CEO, Springer Nature

Okay, Nick. Thank you very much. Let me start with the first question first. Essentially, your question is to what extent will full open access be part of transformative agreements. The transformative agreements in principle are only relevant for the subscription and hybrid journals in our Springer Nature portfolio. Basically, they don't cover full open access journals. There's a handful of customers where we have negotiated to include full open access agreements, together with a transformative agreement in a single commercial agreement. But it's actually only a handful of them, mostly in Europe. It's a couple of them, and we haven't really seen, let's say, an acceleration of that over the past couple of years. I mean, maybe one or two every year.

It's also driven by the fact that full open access, quite often, as you rightly said, is funded outside of the library, and the library will say, "Well, I just don't have the funds to include those full open access journals into my budget." So that was your first question. The second question was around, let's say, capital M&A, or let's say our capital allocation policy and M&A. You want to take that one, Patric?

Patric Somlo
CFO, Springer Nature

Yeah, happy to do so, Frank. Nick, when we did the IPO, we had a leverage of about 3x , and we are now at 1.6 x, which is at the lower end of our target range. We are actually very happy with the progress we made. As mentioned in the past, our priorities for utilizing the cash flow are clear. We first will invest in our business, maintain our strong balance sheet, look forward for value-enhancing M&A, and pay a progressive dividend. Beyond that, if our strong cash generation leads to excess capital beyond the needs of our business, we will consider returning it to shareholders. But of course, we take the liquidity of our shares into account if you make those decisions.

Frank Vrancken Peeters
CEO, Springer Nature

Yeah. Does that answer your questions, Nick?

Nick Dempsey
Analyst, Barclays

Thank you, guys.

Frank Vrancken Peeters
CEO, Springer Nature

Okay. Thank you.

Operator

The next question comes from David Nolan from Morgan Stanley. Please go ahead.

David Nolan
Analyst, Morgan Stanley

Afternoon, everyone. Thanks for taking my questions. One for me, a follow-up on the TA agreement. So, recent transformative agreements with Cornell, University of Texas, and some in Brazil as well, do point towards more of a use of uncapped OA publishing. Can you give us a sense of what proportion exactly of your TA portfolio is already uncapped? Then just connected to that, like how that impacts the relationship between revenue and submissions? To follow up on the previous as well. Thank you.

Frank Vrancken Peeters
CEO, Springer Nature

Sorry, David, I didn't get your second question. It was a bit too fast for me.

David Nolan
Analyst, Morgan Stanley

I mentioned the relationship between article volumes and revenue growth as if there's more of a preference to moving to fully uncapped—

Frank Vrancken Peeters
CEO, Springer Nature

Okay. You are right. I mean, we have signed TAs with uncapped volumes. I think it is fair to say that, and Patric, who only recently joined us, but he will probably see that in the months to come, is that if you look at our transformative agreements, unfortunately, we have more than 100 of them, and most of them are different. We have transformative agreements where, for instance, we have a ceiling and a floor. We have transformative agreements where basically customers are allowed to roll over articles. We have transformative agreements like the one in Germany, which is basically on an article-by-article basis, and we also have agreements where it is basically an unlimited amount of articles.

What that means in practice is that the commercial terms for those agreements do actually take article growth into account, so we kind of make it a projection of what we expect in terms of article growth, and that will then reflect the commercial terms for that agreement. Then basically, revenue recognition is done on a kind of time basis and not on a kind of volume basis as we do with our transformative agreements that are, let us say, not uncapped. I hope that answers your question.

David Nolan
Analyst, Morgan Stanley

That is helpful. Thank you, Frank.

Frank Vrancken Peeters
CEO, Springer Nature

Okay. Thank you.

Operator

The next question comes from Steve Liechti from Deutsche Bank. Please go ahead.

Steve Liechti
Analyst, Deutsche Bank

Yeah. Hi there. I've got two then, please. Thank you very much. One is just, can you remind us how much of your business in journals is humanities and social sciences now? And if you had an opportunity to expand that, would that be interesting to you relative to hard science and medicine? That's the first question. And second question, can you just give us a bit more color on ARC3 in the kind of subscription, longer-term subscription-type deals, progress there, please? Thanks.

Frank Vrancken Peeters
CEO, Springer Nature

Yeah. So, thank you, Steve. I'll start with the ARC3 one, and then I will come back to the, let's say, HSS question and possible acquisitions. So if I start with ARC3, I think it's always important to remind ourselves that researchers publish with us to get maximum visibility for their research insights, and as such, we have a responsibility to give them that visibility in any environment. Now, if you look at ARC3, it's basically an extension of our longstanding TDM business. We announced ARC3 earlier in the year. ARC3 is actually a proposition that provides for the use of Springer Nature full text for AI use cases with clear guardrails around provenance and attribution, and also a sustainable business model. So we don't like one-offs, but it's a subscription model.

We're seeing good interest in ARC3 from a wide range of customers, including corporate and academic customers, so we're actually quite happy with the progress on ARC3. Now, your question around HSS, and I guess also a kind of subtle question around M&A. If you look at HSS content today, it's a little bit less than 10% of our total articles that we publish, so I would say it's a small part of the portfolio. Coming back to the question around M&A, and I guess you're referring here to one of our competitors that has announced certain plans. I think you know that M&A is part of our DNA. If you look at Springer Nature, we're the result of a merger, and prior to the merger, we are the result of many acquisitions. So we have done a lot of investments and also divestments over the past couple of years.

It's fair to say that we evaluate every opportunity on its own merit, looking at how this fits strategically within our portfolio and also how it could impact our financials. I assume you understand that I will not make any further comments about the kind of hidden question you had in your question, so I hope you have understanding for that.

Steve Liechti
Analyst, Deutsche Bank

Okay, thanks.

Frank Vrancken Peeters
CEO, Springer Nature

Okey-doke.

Operator

The next question comes from James Tate from Goldman Sachs. Please go ahead.

James Tate
Analyst, Goldman Sachs

Thank you. Good afternoon. It's James Tate from Goldman. I got two questions, please. Firstly, just in terms of the 2027 renewal season, you noted it's progressing as expected. Are you seeing any differences in trends by region, whether North America versus Europe and Asia, in terms of customer behavior or renewal economics? It would be helpful to get some color here. Secondly, in terms of the U.S. regulatory environment, could you provide an update on your thoughts regarding the OMB proposals, where I believe a decision is expected in mid-December? Thank you.

Frank Vrancken Peeters
CEO, Springer Nature

Yeah. Thank you, James. If you look at our renewal process, it is important to remember that, of course, renewals is about 60% of our research revenue. That is the contracted part. And those contracts typically have a multi-year duration, let us say, between three to five years. So every year, we are renewing roughly 20% of those contracts every year. As I mentioned during the presentation, we are close to 100% on renewals for 2026, and the 2027 renewals are progressing as expected. Obviously, if you look at the different regions, in certain regions, we will have one year heavier load in terms of active renewals than in others. But overall, I think we are actually quite happy with the progress that we are making, and it is in line with our expectation. Your second question, update on the U.S. As we have mentioned in previous calls, Springer Nature is a diversified business.

Roughly 1/4 of our revenues and a low double-digit percentage of the articles that we publish are from the U.S., and about half of those are the result of federally funded research, for instance, by the NIH or the NSF. If you look at the OMB guidelines that published in May, they actually proposed quite significant changes to funding policies, such as prohibiting the use of APCs, subscription costs, or conference fees, but also introducing new political oversight on funding allocations. If you see what the reaction was, it actually resulted in a strong, largely negative reaction from the research community, attracting over 500,000 comments. And typically, what you see in these type of situations is that people just put their signature under a comment. In this case, it being mostly scientists, I think it is fair to say that it was almost 500,000 individual, separate, different comments.

It just shows how, let us say, the community reacted to this. As a result, we saw that the Congress paused the implementation of the proposals up until at least mid-December, and obviously now, after the midterm results, it remains to be seen if this proposal continues to be a priority for the administration. So I guess at this stage, it is just wait and see, but I think it is also fair to say that it received a lot of attention, and the question is, of course, whether this is still a priority for the current administration.

James Tate
Analyst, Goldman Sachs

Thank you.

Operator

The next question comes from Will Packer from BNP Paribas. Please go ahead.

Will Packer
Analyst, BNP Paribas

Hi there. Thanks for taking my questions. A couple from me. Firstly, I just wondered whether you could share any perspectives on whether the industry as a whole will experience accelerating revenue growth in 2027 versus 2026, and the key factors at play, and perhaps any sense of market share considerations as we head into next year. Secondly, Springer and other peers have talked to the impressive article submission growth that we've seen. Could you just confirm what portion of those submitted articles are repeat submissions? Have some already been submitted elsewhere in the journal ecosystem and are now trying different journals and cascading down? So just sort of underlying growth in article submissions. Thanks.

Frank Vrancken Peeters
CEO, Springer Nature

Yeah. Thank you very much, Will. So maybe start with, let's say, expectations for 2027. We actually do expect that the market to remain healthy, driven by, as I shared in the presentation, the continued globalization of research, but also the impact of AI. We are confident that we will be able to outperform the market, very much supported by the strength of our portfolio, but also the investments we have made, like launching new journals, investing in technology, and expansion in Asia. So yeah, all in all, I think a good positive outlook in terms of market expectation. If we look at Springer Nature itself, our submissions continue to be strong. The renewal process is going as expected. Yeah, and you can expect from us, let's say, updated guidance next year when we release our 2026 full-year results.

Now, the other question that you had is, if you look at the, let's say, sustainability of submissions and to what extent resubmissions are part of that, I think it's fair to say that submissions continue to be very strong. I just explained that the market is strong, and against that strong market environment, we are doing better. What we also see is that, of course, acceptance rates vary quite a lot across different regions in the world, Europe and U.S. Typically have a higher accept rate than, for instance, Asia. But what we also see is that as markets mature more, the accept rate improves and citations also improve. So that's a positive outlook. Now, if you look at resubmissions, yes, those are part of our submission growth. Unfortunately, I cannot give you the precise number of what is unique submissions versus resubmissions.

But what you typically see is that if authors are not accepted by a journal, they might pick another journal in our portfolio, but they also might pick a journal from our competitors. At the same time, of course, tools like T-Rex help guide authors to the right journal within our portfolio. Yes, resubmissions are part of the total submission growth. I cannot give you the percentage right now, but I would say that the lion's share, of course, is original submissions.

Will Packer
Analyst, BNP Paribas

Thanks for the color.

Frank Vrancken Peeters
CEO, Springer Nature

Yep, thank you.

Operator

The next question comes from Conor O'Shea from Kepler Cheuvreux. Please, go ahead.

Conor O'Shea
Analyst, Kepler Cheuvreux

Yes. Good afternoon. Thanks for taking my questions. My two questions are, firstly, just in terms of like-for-like growth in research accelerating sequentially in the third quarter against, I think, article publish growth, which was slightly slower than the first half. I know you do not like to look at it too closely quarter by quarter as it does not align, but just wondering were there any other factors, maybe around book release, that were favorable to the third quarter that might explain the acceleration, or were there other factors? Then the second question, just in terms of the margins for the fourth quarter, I know you look at that on a full-year basis, but any factors to take into account?

Obviously, there will be a positive boost from scope again in Q4, but any reason why research margins in particular might be down year-on-year in Q4 at this stage, or should we be looking at least flat or slightly up? Thank you.

Frank Vrancken Peeters
CEO, Springer Nature

I think two questions. The way I interpret them, in a way, it is about comparing nine-month results to the full-year results. As you have seen, we have updated our guidance to at least 6%. I think it is fair to say that if I look at where the business is over the first nine months, I do not expect a lot of change towards the end of the year. So we would actually expect continued growth rates as we have shown so far, and also the margin expansion to continue up until the end of the year. Keeping in mind that, of course, if you look at the different units, research, there tends to be some transactional revenue at the end of the year. We have taken that on board in our guidance.

If you look at, let us say, health and education, typically the last quarter for health is a little bit bigger, and for education, the last quarter is a relatively smaller quarter. So that is kind of the color I can give on the full-year expectation.

Conor O'Shea
Analyst, Kepler Cheuvreux

Okay. Fair enough. Thank you.

Operator

The next question comes from Ciarán Donnelly from Citi. Please, go ahead.

Ciarán Donnelly
Analyst, Citi

Yeah, thanks. Couple questions left myself. One just on Nature Research Assistant. Can you talk about the monetization path in 2027 onwards, and how significant of a contributor could that be, on a short to medium-term view? And maybe just connected to that, again, going back to M&A priorities, is this space an area where you could look to be active on a bolt-on strategy in terms of building out those capabilities, given leverages within your target range? And then maybe one question just historically on big pieces of like-for-like publishing M&A you've done. Can you just talk us through the level of synergies you typically would look to achieve in some of these larger acquisitions? Thanks.

Frank Vrancken Peeters
CEO, Springer Nature

Yeah. So essentially, three questions. The first one, I'll try to be quick and short. On Nature Research Assistant, the answer is very simple. We don't expect a significant revenue contribution next year. As mentioned, we want to do a launch early in the year, and our initial focus shall be very much on growing the user base and less so on monetization. The next question was around M&A. What is our focus for M&A? Our focus from M&A is to support the growth areas of the business, so that's essentially anything that supports the growth in open access. That's really the key priority. Second, of course, we look at, let's say, technology. For instance, AI-driven businesses that can help us to basically progress our AI agenda. We've looked at certain assets. So far, not yet fully convinced of, let's say, the value that they have.

So that is on that part. Your third question was essentially if you look at, let us say, our capital allocation and our ability to do M&A. I think we are in a good position, as Patric explained. From that perspective, I think our capital allocation and our current leverage actually allows for M&A to support that. Did I fully answer your question, or?

Ciarán Donnelly
Analyst, Citi

The last one was just on historic M&A that you have done.

Frank Vrancken Peeters
CEO, Springer Nature

Oh, yeah.

Ciarán Donnelly
Analyst, Citi

And level of synergies that you have historically achieved—

Frank Vrancken Peeters
CEO, Springer Nature

Yeah.

Ciarán Donnelly
Analyst, Citi

—or would expect to achieve.

Frank Vrancken Peeters
CEO, Springer Nature

Yeah, good question. I think, of course, at Springer Nature, we have some experience in M&A. I've had some experience in prior lives in this industry on M&A as well. From a cost perspective, there are synergies. A significant part of the cost base is fixed, and that's also why you see operating leverage and expanding margins at Springer Nature. You only need one platform to distribute your journals. You can benefit from, let's say, economies of scale with your external suppliers. Of course, your overheads can support. So there's definitely, let's say, economies of scale. I think it very much depends on the asset and how well it fits. So difficult to give any precise numbers here, but there's definitely economies of scale if you bring different publishers together. Then it very much depends how much overlap there is in the footprint.

I think if you look at the Springer Nature combination at the time, it was attractive from a cost perspective, but actually what was equally important is that in a way, it brought for Springer, of course, the prestige of the Nature brand into the organization. Actually for the Nature journal, it helped it to reach a global audience through the sales and marketing capabilities of the Springer organization. Also the Springer organization was pretty strong in terms of technology and operational excellence. So I think there's always more than just the financial part in such a situation.

Ciarán Donnelly
Analyst, Citi

Okay. Thanks, Frank.

Operator

Our last question comes from Konrad Zomer from ABN AMRO - ODDO BHF. Please go ahead.

Konrad Zomer
Analyst, ABN AMRO and ODDO BHF

Hi. Thanks for taking my questions. The first one is on research. You mentioned 12% growth in articles submitted. Can you share with us what the percentage growth was in the first nine months for your full open access portfolio? My second question is on the benefits of AI. Do you think that where you are today have the benefits that you've implemented been mostly on revenue growth or on cost efficiency? Thank you.

Frank Vrancken Peeters
CEO, Springer Nature

Yeah. So two questions. The first one, if you look at our submission growth and publication growth that we had in H1 and now at nine months, in both cases, submission growth was above 30%, publication growth above 12%, and in both cases, actually, open access sits well above that percentage. So open access is growing faster than the average of our portfolio. Now, the second question around AI. Yes, I think it's fair to say that our initial focus on, let's say, making use of AI was very much on, let's say, the service we bring to the community, because that's where we see the biggest opportunity in using AI to create a frictionless publication process. I think we're starting to see the benefits of that. At the same time, yes, AI also helps us to improve our margin.

The margin is not only improving as a result of AI. There's more levers to that, operational leverage, but also, of course, the fact that we have quite a broad scope, let's say, efficiency program under the Horizon banner. That's a program that we started a couple of years, and every year, we try to evaluate, can we add new programs to that overall, new projects to that overall program? Now, if you look at AI is also having an impact on efficiency within Springer Nature. It helps us to speed up, let's say, our development in our engineering teams. It helps us to reduce costs in some of our overhead functions like HR, finance, and others, and also in the publication process. I think I shared that before.

If you look at something like ACDCx, it actually automates the typesetting, which results in a cost reduction for each manuscript that we process. Yes, I think it's fair to say that the priority for AI at the moment is very much on, let's say, the revenue side of the business, but at the same time, we are actually also executing AI programs to drive efficiency internally.

Konrad Zomer
Analyst, ABN AMRO and ODDO BHF

Thanks very much.

Operator

We have a follow-up question from Nick Dempsey from Barclays. Please go ahead.

Nick Dempsey
Analyst, Barclays

Yeah, thanks, guys. Just squeezing in another one. Just on education in the quarter, I mean, there was clearly a decent-sized boost from FX on year-on-year reported revenue growth, and I expect on margins too. Can you just help us out where that's coming from and what we should expect in the next couple of quarters around FX in education?

Frank Vrancken Peeters
CEO, Springer Nature

Yeah. Well, Patric, do you want to take a run?

Patric Somlo
CFO, Springer Nature

Yeah. I mean, on the FX, to have expectations on how it moves, this is difficult to predict. But I think what we have that should help you, Nick, is in the appendix, there is also a sensitivity table on what is the margin impact, how different FX rates are moving, and this is something I suggest that you can guide. Then, you mentioned also Mexico in the press release, and that should also give you some indication.

Nick Dempsey
Analyst, Barclays

That was the big one that caught us. I mean, we were probably all wrong on FX. Was Mexico the big one that probably caught us out, do you think?

Patric Somlo
CFO, Springer Nature

Yes.

Nick Dempsey
Analyst, Barclays

Okay. Thanks.

Frank Vrancken Peeters
CEO, Springer Nature

Okay. Thank you, Nick.

Operator

Ladies and gentlemen, this concludes today's question and answer session. Back over to you for any closing remarks.

Frank Vrancken Peeters
CEO, Springer Nature

Well, thank you all for your attention. Of course, Patric, thanks for joining us for the first call. Only two weeks in the role, so I am very happy to have you on board. Thank you all for your attention and wish you a lovely day.

Operator

Ladies and gentlemen, the conference is now over. Thank you for choosing Chorus Call, and thank you for participating in the conference. You may now disconnect your lines. Goodbye.